HeyJaredJulie Ehlers
- Indexed articles, last 90 days
- 24
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Clinical Advisor
- Top 1M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
EHA 2026 Highlights: The Latest Research on Acute Myeloid Leukemia (opens the original)
Read excerpt
The European Hematology Association 2026 Congress featured cutting-edge research on the latest treatment strategies for acute myeloid leukemia (AML). Read on for our picks for the most impactful AML research presented at the meeting. The phase 1 SNDX-5613-0708 trial (NCT06226571) enrolled patients aged 18-75 years with newly diagnosed AML harboring KMT2Ar, NPM1m, or NUP98r who were eligible for intensive chemotherapy.1 The patients received either revumenib 110 mg/220 mg, with or without a stron
ARTEMIS-008: Risvutatug Rezetecan ‘Potential New Standard of Care’ in Relapsed SCLC (opens the original)
Read excerpt
Treatment with risvutatug rezetecan (ris-rez) improves survival in relapsed small cell lung cancer (SCLC) compared with topotecan, according to research presented at the 2026 World Conference on Lung Cancer. At a median follow-up of 12.2 months, the median overall survival (OS), the study’s primary endpoint, was 18.5 months with ris-rez and 10.3 months with topotecan (hazard ratio [HR], 0.46; 95% CI, 0.35-0.62; P <.0001). “The [ARTEMIS-008] trial positions ris-rez as a potential new standard of
Subcutaneous DISC-3405 Safely Lowers Phlebotomy Rates in Polycythemia Vera (opens the original)
Read excerpt
The use of DISC-3405, a subcutaneously administered, humanized IgG1 monoclonal antibody that targets TMPRSS6, decreases the need for phlebotomy in patients with polycythemia vera (PV), according to research presented in a poster at the Society of Hematologic Oncology 2026 Annual Meeting. The standard-of-care treatment for PV involves phlebotomy and cytoreductive therapies, which can negatively affect quality of life and, in the case of phlebotomy, lead to iron deficiency, researchers explained.
Subcutaneous DISC-3405 Safely Lowers Phlebotomy Rates in Polycythemia Vera - Oncology Nurse Advisor (opens the original)
Read excerpt
The use of DISC-3405, a subcutaneously administered, humanized IgG1 monoclonal antibody that targets TMPRSS6, decreases the need for phlebotomy in patients with polycythemia vera (PV), according to research presented in a poster at the Society of Hematologic Oncology 2026 Annual Meeting. The standard-of-care treatment for PV involves phlebotomy and cytoreductive therapies, which can negatively affect quality of life and, in the case of phlebotomy, lead to iron deficiency, researchers explained.
Trust in Government Agencies as Source of Cancer Information Has Declined Since COVID-19 Pandemic (opens the original)
Read excerpt
Trust in government health agencies as sources of cancer information decreased during and after the COVID-19 pandemic, according to research published in JAMA Network Open. Trust in charitable organizations and family/friends as sources of cancer information also decreased over this period, study researchers reported. “During the COVID-19 pandemic, trust in traditional health authorities in the US was tested amid rapidly changing guidance, competing narratives, and widespread misinformation,” th
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For Clinical Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.